Real-world results for hepatitis C drugs have been very closely aligned to the clinical trial outcomes, which is likely due to a combination of factors, such as the effectiveness of the agents and better knowledge of using direct-acting antivirals, according to Gail Bridges, PharmD, of Accredo Health.
Real-world results for hepatitis C drugs have been very closely aligned to the clinical trial outcomes, which is likely due to a combination of factors, such as the effectiveness of the agents and better knowledge of using direct-acting antivirals, according to Gail Bridges, PharmD, of Accredo Health.
Transcript
How do the real-world results of the hepatitis C virus drugs Harvoni and Viekira Pak hold up to the results that were reported in the clinical trials?
Our data indicate that Accredo's patients achieve results that are right on point with the clinical trials. In our study patients achieved an average sustained viral response rate, which is really the clinical surrogate marker for cure, of 96%. And this was on par with the mid-90% range that each of these individual therapies described in their clinical trials.
Why do you think the real-world outcomes hold up so well to the clinical trial results?
I think a number of factors contribute to the successful results that we saw in our study. First, clearly these are very effective agents and we are becoming savvier as a medical community about use of the direct-acting antivirals. We have very robust guidelines to help us make smart choices, to help prescribers and plan sponsors match up patients with the regimen that most closely meets their specific needs. And, lastly, we placed a great deal of emphasis on adherence and education specific to hepatitis C, the drugs and the disease, to help these patients really succeed with these therapies.
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More